Cancer

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

–  Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first…

10 months ago

BioNTech Announces Planned Retirement of Sean Marett

Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean…

10 months ago

Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024

OGAP®-Verify allows for significantly enhanced sensitivity and specificity for improved target selection, dramatically accelerating drug target discoveryOGAP-Verify is now more…

10 months ago

AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer’s Conference

STOCKHOLM, SWEDEN / ACCESSWIRE / March 7, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a…

10 months ago

AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in…

10 months ago

New Swedish Clinical Study Published In The British Journal Of Dermatology Demonstrates Superiority Of AI-Algorithm Guided Melanoma Diagnosis

Dermalyser AI-driven support tool achieved remarkable sensitivity and specificity values of 95% and 85%, respectively, with these figures increasing to…

10 months ago

Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma

LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals,…

10 months ago

Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma

Submission supported by data from Phase 3 PERSEUS study, which showed the daratumumab subcutaneous formulation-based regimen significantly reduced the risk…

10 months ago

NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan(R) in Ovarian and Related Cancers

LEXINGTON, KY / ACCESSWIRE / March 5, 2024 / NX Development Corp. (NXDC) has achieved another milestone as we proudly…

10 months ago

Cantargia Reports New Preclinical Data on Antitumor Effects of Nadunolimab in Pancreatic Cancer

LUND, SE / ACCESSWIRE / March 5, 2024 / Cantargia (STO:CANTA) (Cantargia AB);(Nasdaq Stockholm: CANTA) today reported new preclinical data…

10 months ago